Research ExplorerPublicationsTemporal changes of patient characteristics over 12 years in...

Temporal changes of patient characteristics over 12 years in a single-center transcatheter aortic valve implantation cohort

Standard

Temporal changes of patient characteristics over 12 years in a single-center transcatheter aortic valve implantation cohort. / Demal, Till Joscha; Weimann, Jessica; Ojeda, Francisco Miguel; Bhadra, Oliver D; Linder, Matthias; Ludwig, Sebastian; Grundmann, David; Voigtländer, Lisa; Waldschmidt, Lara; Schirmer, Johannes; Schofer, Niklas; Blankenberg, Stefan; Reichenspurner, Hermann; Conradi, Lenard; Seiffert, Moritz; Schaefer, Andreas.

In: CLIN RES CARDIOL, Vol. 112, No. 5, 05.2023, p. 691-701.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Demal, TJ, Weimann, J, Ojeda, FM, Bhadra, OD, Linder, M, Ludwig, S, Grundmann, D, Voigtländer, L, Waldschmidt, L, Schirmer, J, Schofer, N, Blankenberg, S, Reichenspurner, H, Conradi, L, Seiffert, M & Schaefer, A 2023, 'Temporal changes of patient characteristics over 12 years in a single-center transcatheter aortic valve implantation cohort', CLIN RES CARDIOL, vol. 112, no. 5, pp. 691-701. https://doi.org/10.1007/s00392-023-02166-8

APA

Demal, T. J., Weimann, J., Ojeda, F. M., Bhadra, O. D., Linder, M., Ludwig, S., Grundmann, D., Voigtländer, L., Waldschmidt, L., Schirmer, J., Schofer, N., Blankenberg, S., Reichenspurner, H., Conradi, L., Seiffert, M., & Schaefer, A. (2023). Temporal changes of patient characteristics over 12 years in a single-center transcatheter aortic valve implantation cohort. CLIN RES CARDIOL, 112(5), 691-701. https://doi.org/10.1007/s00392-023-02166-8

Vancouver

Demal TJ, Weimann J, Ojeda FM, Bhadra OD, Linder M, Ludwig S et al. Temporal changes of patient characteristics over 12 years in a single-center transcatheter aortic valve implantation cohort. CLIN RES CARDIOL. 2023 May;112(5):691-701. https://doi.org/10.1007/s00392-023-02166-8

Bibtex

@article{0af3a37d0896436ba9769b9c2f0d8cb4,
title = "Temporal changes of patient characteristics over 12 years in a single-center transcatheter aortic valve implantation cohort",
abstract = "BACKGROUND: Beneficial results of transcatheter aortic valve implantation (TAVI) compared to surgical aortic valve replacement (SAVR) in patients at all risk strata have led to substantial changes in guideline recommendations for valvular heart disease.AIM: To examine influence of these guideline changes on a real-world TAVI cohort, we evaluated how risk profiles and outcomes of TAVI patients developed in our single-center patient cohort over a period of 12 years.METHODS: Baseline, procedural and 30-day outcome parameters of TAVI patients were retrospectively compared between three time periods (period 1: 2008-2012, period 2: 2013-2017, period 3: 2018-2020).RESULTS: Between 03/2008 and 12/2020, a total of 3678 patients underwent TAVI at our center. The median age was 81.1 years (25th, 75th percentile: 76.7, 84.9) with no significant change over time. The EuroSCORE II showed a continuous and significant decline from 5.3% (3.3, 8.6) in period 1 to 2.8% (1.7, 5.0) in period 3 (p < 0.001). Furthermore, rates of permanent pacemaker implantation, acute kidney injury, and paravalvular leakage ≥ moderate continuously declined over time. Accordingly, the 30-day mortality fell from 9.3% in period 1 to 4.3% in period 3 (p < 0.001).CONCLUSION: Despite substantial guideline alterations, median patient age remained largely unchanged in our TAVI cohort over the past 12 years. Therefore, increased age still appears to be the main reason to choose TAVI over SAVR. However, risk profiles declined substantially. Significant improvements in early outcomes suggest favorable influence of less invasive access routes, improved device platforms and growing user experience.",
keywords = "Humans, Aged, 80 and over, Child, Transcatheter Aortic Valve Replacement/adverse effects, Aortic Valve Stenosis/diagnosis, Retrospective Studies, Risk Factors, Treatment Outcome, Aortic Valve/diagnostic imaging, Heart Valve Prosthesis Implantation/adverse effects",
author = "Demal, {Till Joscha} and Jessica Weimann and Ojeda, {Francisco Miguel} and Bhadra, {Oliver D} and Matthias Linder and Sebastian Ludwig and David Grundmann and Lisa Voigtl{\"a}nder and Lara Waldschmidt and Johannes Schirmer and Niklas Schofer and Stefan Blankenberg and Hermann Reichenspurner and Lenard Conradi and Moritz Seiffert and Andreas Schaefer",
note = "{\textcopyright} 2023. The Author(s).",
year = "2023",
month = may,
doi = "10.1007/s00392-023-02166-8",
language = "English",
volume = "112",
pages = "691--701",
journal = "CLIN RES CARDIOL",
issn = "1861-0684",
publisher = "D. Steinkopff-Verlag",
number = "5",

}

RIS

TY - JOUR

T1 - Temporal changes of patient characteristics over 12 years in a single-center transcatheter aortic valve implantation cohort

AU - Demal, Till Joscha

AU - Weimann, Jessica

AU - Ojeda, Francisco Miguel

AU - Bhadra, Oliver D

AU - Linder, Matthias

AU - Ludwig, Sebastian

AU - Grundmann, David

AU - Voigtländer, Lisa

AU - Waldschmidt, Lara

AU - Schirmer, Johannes

AU - Schofer, Niklas

AU - Blankenberg, Stefan

AU - Reichenspurner, Hermann

AU - Conradi, Lenard

AU - Seiffert, Moritz

AU - Schaefer, Andreas

N1 - © 2023. The Author(s).

PY - 2023/5

Y1 - 2023/5

N2 - BACKGROUND: Beneficial results of transcatheter aortic valve implantation (TAVI) compared to surgical aortic valve replacement (SAVR) in patients at all risk strata have led to substantial changes in guideline recommendations for valvular heart disease.AIM: To examine influence of these guideline changes on a real-world TAVI cohort, we evaluated how risk profiles and outcomes of TAVI patients developed in our single-center patient cohort over a period of 12 years.METHODS: Baseline, procedural and 30-day outcome parameters of TAVI patients were retrospectively compared between three time periods (period 1: 2008-2012, period 2: 2013-2017, period 3: 2018-2020).RESULTS: Between 03/2008 and 12/2020, a total of 3678 patients underwent TAVI at our center. The median age was 81.1 years (25th, 75th percentile: 76.7, 84.9) with no significant change over time. The EuroSCORE II showed a continuous and significant decline from 5.3% (3.3, 8.6) in period 1 to 2.8% (1.7, 5.0) in period 3 (p < 0.001). Furthermore, rates of permanent pacemaker implantation, acute kidney injury, and paravalvular leakage ≥ moderate continuously declined over time. Accordingly, the 30-day mortality fell from 9.3% in period 1 to 4.3% in period 3 (p < 0.001).CONCLUSION: Despite substantial guideline alterations, median patient age remained largely unchanged in our TAVI cohort over the past 12 years. Therefore, increased age still appears to be the main reason to choose TAVI over SAVR. However, risk profiles declined substantially. Significant improvements in early outcomes suggest favorable influence of less invasive access routes, improved device platforms and growing user experience.

AB - BACKGROUND: Beneficial results of transcatheter aortic valve implantation (TAVI) compared to surgical aortic valve replacement (SAVR) in patients at all risk strata have led to substantial changes in guideline recommendations for valvular heart disease.AIM: To examine influence of these guideline changes on a real-world TAVI cohort, we evaluated how risk profiles and outcomes of TAVI patients developed in our single-center patient cohort over a period of 12 years.METHODS: Baseline, procedural and 30-day outcome parameters of TAVI patients were retrospectively compared between three time periods (period 1: 2008-2012, period 2: 2013-2017, period 3: 2018-2020).RESULTS: Between 03/2008 and 12/2020, a total of 3678 patients underwent TAVI at our center. The median age was 81.1 years (25th, 75th percentile: 76.7, 84.9) with no significant change over time. The EuroSCORE II showed a continuous and significant decline from 5.3% (3.3, 8.6) in period 1 to 2.8% (1.7, 5.0) in period 3 (p < 0.001). Furthermore, rates of permanent pacemaker implantation, acute kidney injury, and paravalvular leakage ≥ moderate continuously declined over time. Accordingly, the 30-day mortality fell from 9.3% in period 1 to 4.3% in period 3 (p < 0.001).CONCLUSION: Despite substantial guideline alterations, median patient age remained largely unchanged in our TAVI cohort over the past 12 years. Therefore, increased age still appears to be the main reason to choose TAVI over SAVR. However, risk profiles declined substantially. Significant improvements in early outcomes suggest favorable influence of less invasive access routes, improved device platforms and growing user experience.

KW - Humans

KW - Aged, 80 and over

KW - Child

KW - Transcatheter Aortic Valve Replacement/adverse effects

KW - Aortic Valve Stenosis/diagnosis

KW - Retrospective Studies

KW - Risk Factors

KW - Treatment Outcome

KW - Aortic Valve/diagnostic imaging

KW - Heart Valve Prosthesis Implantation/adverse effects

U2 - 10.1007/s00392-023-02166-8

DO - 10.1007/s00392-023-02166-8

M3 - SCORING: Journal article

C2 - 36792752

VL - 112

SP - 691

EP - 701

JO - CLIN RES CARDIOL

JF - CLIN RES CARDIOL

SN - 1861-0684

IS - 5

ER -